Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
about
Virologic Tools for HCV Drug Resistance TestingUpdate on hepatitis C: Direct-acting antiviralsInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceComparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase InhibitorsTemporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected IndividualHepatitis C virus replicons: dinosaurs still in business?Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C VirusDiscovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.Discovery of N -[4-[6- tert -Butyl-5-methoxy-8-(6-methoxy-2-oxo-1 H -pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B PolymeraseViral replication. Structural basis for RNA replication by the hepatitis C virus polymeraseSimilar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingMechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve PatientsA screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundUpdate on different aspects of HCV variability: focus on NS5B polymerase.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Variability of the polymerase gene (NS5B) in hepatitis C virus-infected women.Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb bindersOccurrence of genetic modifications in core, 5'UTR and NS5b of HCV associated with viral response to treatment.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence researchAnalysis of a non-structural gene reveals evidence of possible hepatitis C virus (HCV) compartmentalization.Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor TherapyAnti-HCV drugs in the pipeline.Resistance mechanisms in HCV: from evolution to intervention.In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitorAvoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.New NS5B polymerase inhibitors for hepatitis C.Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.Current drug discovery strategies for treatment of hepatitis C virus infection.Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.
P2860
Q26774374-37C3A8BF-5FF9-4C8F-9C63-6100FD79E57BQ26775809-25B82AC0-A6B9-4335-A3E0-5E3480F06B10Q26783056-4FFBF058-5089-4C43-9346-739B76729EC3Q27486813-44AE78A8-D3F9-4734-8D3A-9BF09766C613Q27488198-02A29D31-B9A9-4C46-9012-AC2554DD5307Q27488905-930ED13D-2732-42C0-BE38-A6CE6E9DB800Q27490222-2C2A89A0-BDA4-45DC-9247-A9CB1D0C2014Q27490956-7EFD948D-0781-444A-822C-097113952CBAQ27680074-343D3A33-600F-4277-BE8A-B704359EAD8FQ27680539-A4520C80-687B-42D8-9974-E712E4BACB52Q27697984-57F8C8A0-7266-487C-BFA6-3790DB921828Q28542443-10B660F3-2AC8-4ED3-A5E9-E45323A4ACFCQ30318760-250AAE00-AD46-40EA-AF8D-1146BEFBFEE3Q32183060-FE349E99-8C88-4898-AA45-1E61C2D066F5Q33875539-953881F4-79AE-42AA-BEFC-90384AAE59CBQ33918841-795BF03C-7A78-4A6E-8DEC-3EAEA1E09EF3Q34163394-FD4286D3-6229-40A8-899B-D0E5CC7F9AAEQ34409020-AD833FEF-EC32-4A65-AB76-45AD0F27909DQ34489239-C7115490-6F87-40C6-839D-900AC74FFFE4Q34489457-ABD41A7B-4518-4222-9FC4-5D074AB10B7AQ34597666-D008865F-A093-4873-8B76-AFD929346A06Q34896257-B02B926B-FD15-4541-88DA-1210C8986431Q34957256-7DB107DA-26FA-41B5-8752-08D72293D7A9Q35004972-A5547B40-8A73-4D0E-9666-64ABC8C4E0D6Q35008754-2A1627FB-F33B-4CAA-AE05-FBB7BD03AE6AQ35627530-B556DBCB-7ECA-4707-A890-B8DBF5460C8AQ35806182-E065C7D2-BE68-44D3-A595-E82E9E2FC5B0Q36018848-0270442F-69E6-4288-AAF0-FB6AF0929EE3Q36034450-1E659837-5DD1-4373-A85D-A15FDEBA0C15Q36881967-A2E09A2D-0A38-4EE6-994D-906577139BB1Q37177740-7900F2C7-F618-41A8-A433-75F93C4946FCQ37228736-3D85F124-5944-4091-A579-316BC9138F64Q37263558-762B31D5-E874-4228-AB0C-355022541246Q37313166-10829DEF-0D1D-459B-9E21-A0D33EC47841Q37678183-69CC3A2E-4FEC-427C-8102-E702732B37A0Q37714008-DFAEC8F2-F071-4169-B9EF-4E6EC6B5D47DQ37772518-97DFA026-ADCC-4C4D-B37B-7DA4E4499268Q37855863-25C8F082-B478-4100-B6C9-81051DE44167Q37884087-81912C6A-AA1F-4EB0-9D66-0147FB07F315Q37894718-86F7FEAA-8788-4BBF-BBEB-D0F2204CDC23
P2860
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Existence of hepatitis C virus ...... tors among untreated patients.
@en
Existence of hepatitis C virus ...... tors among untreated patients.
@nl
type
label
Existence of hepatitis C virus ...... tors among untreated patients.
@en
Existence of hepatitis C virus ...... tors among untreated patients.
@nl
prefLabel
Existence of hepatitis C virus ...... tors among untreated patients.
@en
Existence of hepatitis C virus ...... tors among untreated patients.
@nl
P2093
P356
P1476
Existence of hepatitis C virus ...... tors among untreated patients.
@en
P2093
Alan Kosaka
Amritha Seshaadri
Hyunsoon Kang
Isabel Nájera
Julian Symons
Nick Cammack
Sonal Rajyaguru
Sophie Chiu
Sophie Le Pogam
P304
P356
10.1093/JAC/DKN085
P407
P577
2008-03-13T00:00:00Z